Chiesi and Protalix’s Therapy for Fabry Disease Receives Marketing Approval from EC
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreJanssen has received its first worldwide approval for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) as EC Authorized treatment
Read moreJapanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb announced on Friday that the European Commission (EC) has awarded the company with
Read moreIlinois-based pharmaceutical company Akorn Operating Co., is under investigation by the Illinois Department of Labor (IDOL), following the company’s filing
Read moreThe European Union has authorized AstraZeneca’s Forxiga (dapagliflozin) to expand the treatment for heart failure (HF) with reduced ejection fraction
Read moreThe European Commission has authorised Sanofi and Regeneron’s Dupixent® (dupilumab) as the first and only therapeutic therapy for eosinophilic esophagitis.
Read moreThe U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use
Read moreThe US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Novavax’s adjuvanted Covid-19 vaccine, NVX-CoV2373, as
Read more